四妙丸合失笑散加减配合前列倍喜胶囊治疗Ⅲ型慢性前列腺炎的观察  

Clinical Observation on Modified Simiao Wan and Shixiaosan Combined with Qianlie Beixi Capsule in Treating Type Ⅲ Chronic Prostatitis with Syndrome of Damp-heat Stagnation

作　　者：张海涛 李恭会[1] 潘正波[2] 徐林飞[2] 卢炜[2] ZHANG Hai-tao;LI Gong-hui;PAN Zheng-bo;XU Lin-fei;LU Wei(Sir Run Shaw Hospital of School of Medicine of Zhejiang University,Hangzhou 310016,China;Taizhou Municipal Hospital,Taizhou 318000,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院,杭州310016 [2]台州市立医院,浙江台州318000

出　　处：《中国实验方剂学杂志》2018年第23期194-199,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：浙江省医药卫生科研项目(2018KY)

摘　　要：目的：观察四妙丸合失笑散加减配合前列倍喜胶囊内服治疗Ⅲ型慢性前列腺炎湿热瘀滞证的疗效,探讨其对Thl/Th2细胞及其细胞因子水平的影响。方法：筛选在就诊的Ⅲ型慢性前列腺炎患者共152例,按数字表法随机分为观察组和对照组各76例。对照组给予前列倍喜胶囊内服治疗,6粒/次,3次/d,饭前服。观察组在对照组治疗的基础上给予四妙丸合失笑散加减,1剂/d,3次/d。两组患者均连续治疗6周。比较两组患者美国国立卫生院制定的慢性前列腺炎症状指数（NIH-CPSI）和湿热瘀滞证症状评分。分析两组患者临床疗效和湿热瘀滞证辨证疗效。检测两组患者外周血Th1,Th2细胞水平以及血清白细胞介素-2（IL-2）,IL-4,IL-6,IL-（-1）0,肿瘤坏死因子-α（TNF-α）,干扰素-γ（IFN-γ）水平。监测两组患者的不良反应发生情况。结果：治疗后,观察组患者疼痛不适、排尿症状、生活质量,NIH-CPSI总分以及湿热瘀滞证症状评分均明显均低于对照组（P〈0.01）。观察组患者临床总有效率为96.05%,显著高于对照组84.21%（P〈0.05）。观察组患者湿热瘀滞证总有效率为97.37%,显著高于对照组84.21%（P〈0.05）。治疗后,观察组患者外周血Th1,Th1/Th2水平明显低于对照组,Th2多于对照组（P〈0.01）。治疗后,观察组血清IL-2,IL-4,IL-（-1）0水平均显著高于对照组,IL-6,TNF-α,IFN-γ水平均明显低于对照组（P〈0.01）。结论：四妙丸合失笑散加减配合前列倍喜胶囊内服治疗Ⅲ型慢性前列腺炎湿热瘀滞证,可明显改善患者的临床症状和证候指标,且可调节Thl/Th2细胞及其细胞因子水平的恢复平衡。Objective： To observe the efficacy of modified Simiao Wan and Shixiaosan combined with Qianlie Beixi capsule in treating type Ⅲ chronic prostatitis with syndrome of damp-heat stagnation,and investigate its effect on levels of Th1/Th2 and cytokines. Method： One hundred and fifty-two type Ⅲ prostatitis patients were selected and randomly divided into control group（ 76 cases） and observation group（ 76 cases） by random number table. The patients in control group were given with Qianlie Beixi capsules（ 6 capsules/time before meals,tid）.Based on the treatment in control group,the patients in observation group were additionally treated with modified Simiao pills and Shixiao San（ 1 dose/day,tid）. Both groups were treated for 6 weeks. Then the scores of National Institutes of Health-chronic prostatitis symptom index（ NIH-CPSI） and symptoms of damp-heat stagnation syndrome（ frequent urination,urine pain,perineum and other local pain,scrotum wet,dripping urine,yellow turbidity,hot and dampness pain） were compared between two groups. The clinical efficacy and syndrome efficacy were analyzed for both groups. Peripheral blood levels of Th1 and Th2 and serum levels of interleukin（ IL）-2,IL-4,IL-6,IL-（-1）0,tumor necrosis factor（ TNF）-α and interferon（ IFN）-γ were detected in two groups. Adverse reactions were also monitored in both groups. Result： After treatment,scores of pain discomfort,urinary symptoms,quality of life,NIH-CPSI total score and damp-heat stagnation symptoms in observation group were obviously lower than those in control group（ P〈0. 01）. Total clinical efficacy rate was 96. 05% in observation group,higher than84. 21% in control group（ P〈0. 05）. Total syndrome efficacy rate was 97. 37% in observation group,higher than84. 21% in control group（ P〈0. 05）. After treatment,peripheral blood levels of Th1 and Th1/Th2 in observation group were lower,while Th2 level was higher than those in control group（ P〈0. 01）. Serum levels of IL-2,IL-4,and IL

关 键 词：四妙丸 失笑散 前列倍喜胶囊 慢性前列腺炎 湿热瘀滞证 

分 类 号：R6[医药卫生—外科学] R69[医药卫生—临床医学]